P
Pedro Santabarbara
Researcher at New York University
Publications - 4
Citations - 1125
Pedro Santabarbara is an academic researcher from New York University. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 3, co-authored 4 publications receiving 1092 citations.
Papers
More filters
Journal ArticleDOI
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
Roman Perez-Soler,Abraham Chachoua,Lisa A. Hammond,Eric K. Rowinsky,Mark S. Huberman,Daniel D. Karp,James Rigas,Gary M. Clark,Pedro Santabarbara,Philip Bonomi +9 more
TL;DR: Erlotinib was active and well tolerated in this patient population, and further clinical development is clearly warranted; cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies.
Journal Article
Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.
David S. Alberts,Alton V. Hallum,Mary Stratton-Custis,Dava J. Garcia,Mary Gleason-Guzman,Sydney E. Salmon,Pedro Santabarbara,Eric J. Niesor,Simon Floret,Craig Bentzen +9 more
TL;DR: In vitro assay results, taken together with preliminary plasma pharmacokinetic data, suggest that Apomine should be clinically active at the 125 mg/m(2) dose level.
Journal ArticleDOI
P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy
Roman Perez-Soler,Abraham Chachoua,Mark S. Huberman,Daniel D. Karp,James R. Rigas,Lisa A. Hammond,Eric K. Rowinsky,Gary M. Clark,Pedro Santabarbara,Philip Bonomi +9 more
Journal Article
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Miguel A. Villalona-Calero,Miguel A. Villalona-Calero,Thierry Petit,John G. Kuhn,Patrick W. Cobb,Maura Kraynak,S. Gail Eckhardt,Ronald Drengler,Cecelia Simmons,Pedro Santabarbara,Daniel D. Von Hoff,Eric K. Rowinsky +11 more
TL;DR: The relative lack of intolerable CNS toxicity at the recommended dose for Phase II studies of crisnatol, 600 mg/m2/day for 9 days, as well as the magnitude of the Css values achieved and the antitumor activity observed at this dose, are encouraging.